While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...
The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback